Researchers
-
Begoña Pina Marín
Ophthalmology
-
Carlos Luis Moser Würth
Ophthalmology
-
Carlos Martínez Belló
Ophthalmology
-
Diana Paola Mora Ramirez
Ophthalmology
-
Joan Josep Escobar Barranco
Ophthalmology
-
Josep Badal Lafulla
Ophthalmology
Phd -
Luis Amselem Gómez
Ophthalmology
-
Magela Garat Chifflet
Ophthalmology
-
Manel Fernández Bonet
Ophthalmology
-
Monica Lecumberri López
Ophthalmology
-
Rafael Alcubierre Bailac
Ophthalmology
-
Sabrina Bojados
Ophthalmology
-
Stephanie Carrillo
Ophthalmology
Contact the group
Form-
García Layana A, Adán A, Ascaso FJ, Cabrera F, Donate J, Escobar Barranco JJ, Peralta G, Reyes García R, Rodríguez Maqueda M, Ruiz-Moreno JM, Vinagre I; MOMENTUM-D Study Group. 324/20
Use of intravitreal dexamethasone implants in the treatment of diabetic macular edema: Expert recommendations using a Delphi approach.
Eur J Ophthalmol. 2020 Sep;30(5):1042-1052.
-
Alcubierre R, Alejaldre A. 274/20
Ocular neuromyotonia of the right third cranial nerve.
J AAPOS 2020 Oct;24(5):298-298.e1
-
Alcubierre R, Sánchez-Dalmau BF, Muñoz S. 269/20
Multiple sclerosis in ophthalmology: beyond optic neuritis.
Med Clin (Ship). 2020 Jul 24;155(2):70-76.
-
Vélez Escolà L, Galán Terraza A, Lagrèze WA, Martín Begué N, Puig Galy J, Velázquez Villoria D, Arcos Algaba G, Mora Ramírez D, García-Arumí J. 108/19
Disc-foveal angle and ocular counterrolling as a key in its interpretation.
Arch Soc Esp Ophthalmol. 2019;94(12):585-590.
-
Alcubierre R, Sánchez-Dalmau BF, Mousavi K. 138/19
Compressive optic neuropathy secondary to allergic reaction to hyaluronidase.
Arch Soc Esp Ophthalmol. 2019;94(9):441-444.
-
Moser CL, Lecumberri Lopez M, Garat M, Martín-Baranera M. 196/19
Prophylactic intracameral cefazolin and postoperative topical moxifloxacin after cataract surgery: endophthalmitis risk reduction and safety results in a 16-year study.
Graefes Arch Clin Exp Ophthalmol. 2019;257(10):2185-2191.
-
Arias L, Cervera E, Vilimelis JC, Escobar JJ, Escobar AG, Zapata MÁ. 144/19
Efficacy and safety of a treat-and-extend regimen with aflibercept in treatment-naive patients with type 3 neovascularization: A 52-Week, Single-Arm, Multicenter Trial.
Retina. 2020 Jul;40(7):1234-1244.
-
Cuesta-Lasso M, Vieira-Barros A, Dolz-Marco R, Roig-Revert MJ, Badal J, Amselem L, Díaz-Llopis M, Gallego-Pinazo R. 1376
Intravitreal therapies for non-neovascular age-related macular degeneration with intraretinal or subretinal fluid.
Arch Soc Esp Ophthalmol. 2017 Mar;92(3):101-106.
-
Juanola X, Loza Santamaría E, Cordero-Coma M; SENTINEL Working Group. (Amselem L). 1377
Description and Prevalence of Spondyloarthritis in Patients with Anterior Uveitis: The SENTINEL Interdisciplinary Collaborative Project.
Ophthalmology. 2016;123(8):1632-6.
-
Monés J, Badal J, Biarnés M. 1374
Feeder vessel laser photocoagulation for idiopathic, subfoveal polypoidal choroidal vasculopathy not responding to either anti-vascular endothelial growth factor therapy or photodynamic therapy.
Retin Cases Brief Rep. 2016 Winter;10(1):100-3.
Projects
-
Ophthalmology
Researcher
- Year 2020
- Comprehensive Care Center Dos de Maig Hospital
Phase III, multicenter, randomized, double-masked and parallel-group study to compare the efficacy, safety, tolerability, pharmacokinetics and immunogenicity of SCD411 and Eylea® in subjects with age-related neovascular macular degeneration.
-
DISTRICT ATTORNEY:
SCD (SamChunDang Pharm. Co.,Ltd)
-
TYPE E:
RD2015
-
Ophthalmology
Researcher
- Year 2020
- Comprehensive Care Center Dos de Maig Hospital
Multicenter Phase Iii Study, Randomized, With Double Masking, Controlled With Active Comparator, To Evaluate The Efficacy And Safety Of Faricimab In Patients With Macular Edema Secondary To Retinal Venous Branch Occlusion.
-
DISTRICT ATTORNEY:
F. Hoffmann-La Roche Ltd.
-
TYPE E:
RD2015
-
Ophthalmology
Researcher
- Year 2020
- Comprehensive Care Center Dos de Maig Hospital
Preliminary randomized, double-masked, 48-week, parallel-group, placebo-controlled demonstrative study to investigate the efficacy and safety of RG7774 in patients with type 1 or type 2 diabetes mellitus with previously untreated diabetic retinopathy.
-
DISTRICT ATTORNEY:
F. Hoffmann-La Roche Ltd
-
TYPE E:
RD2015
-
Ophthalmology
Researcher
- Year 2020
- Comprehensive Care Center Dos de Maig Hospital
Extension, open and multicenter study to evaluate the long-term safety and tolerability of Faricimab in patients with diabetic macular edema.
-
DISTRICT ATTORNEY:
F. Hoffmann-La Roche Ltd
-
TYPE E:
RD2015
-
Ophthalmology
Researcher
- Year 2020
- Comprehensive Care Center Dos de Maig Hospital
Retrospective observational study to evaluate the association between anatomical and clinical results in patients with neovascular age-related macular degeneration (AMD) treated with anti-VEGF in the FRB Registry!.
-
DISTRICT ATTORNEY:
CLINICAL FOUNDATION FOR BIOMEDICAL RESEARCH
-
TYPE E:
EPA-OD
-
Ophthalmology
Researcher
- Year 2020
- Comprehensive Care Center Dos de Maig Hospital
A phase III, multicenter, prospective, randomized, double-masked, active comparator-controlled, two-arm study to evaluate the efficacy and safety of intravitreal KSI-301 compared with intravitreal aflibercept in naïve participants with visual impairment due to macular edema secondary to retinal vein occlusion (RVO).
-
DISTRICT ATTORNEY:
Kodiak Sciences Inc.
-
TYPE E:
RD2015
-
Ophthalmology
Researcher
- Year 2020
- Sant Joan Despí Moisès Broggi Hospital
A phase III, multicenter, prospective, randomized, double-masked, active comparator-controlled, two-treatment arm study to evaluate the efficacy and safety of intravitreal KSI-301 compared with intravitreal aflibercept in naïve participants with secondary visual impairment to diabetic macular edema (DMD).
-
DISTRICT ATTORNEY:
Kodiak Sciences Inc.
-
TYPE E:
RD2015
-
Ophthalmology
Researcher
- Year 2020
- Comprehensive Care Center Dos de Maig Hospital
Phase IIIb/IV, open-label, single-group, 56-week extension study to evaluate the efficacy and safety of brolucizumab 6 mg in a treatment-to-control regimen with maximum treatment intervals of 20 weeks in patients with age-associated neovascular macular degeneration who have completed the CRTH258A2303 (TALON) study.
-
DISTRICT ATTORNEY:
Novartis pharmaceutical, SA
-
TYPE E:
RD2015
-
Ophthalmology
Researcher
- Year 2020
- Sant Joan Despí Moisès Broggi Hospital
Effectiveness of the boost application to predict visual quality in cataract surgery.
-
DISTRICT ATTORNEY:
Monica Lecumberri
-
TYPE E:
PI
-
Ophthalmology
Researcher
- Year 2020
- Sant Joan Despí Moisès Broggi Hospital
Design And Validation Of A Questionnaire For The Telematic Triage Of The First Ophthalmology Visits Derived From The Head Doctor In Primary Care Centers.
-
DISTRICT ATTORNEY:
Stephany Carrillo Cristancho
-
TYPE E:
PI
Lines of action
- Treatment of retinal diseases with intravitreal medication
- Anti VEGF in diabetic macular edema
- Anti VEGF in central serous chorioretinopathy
- Treatment of Diabetic Retinopathy
- UTI (Intravitreal Therapy Unit)
- New techniques in cataract surgery
- Surgical alternatives to full thickness corneal transplantation
- Microkeratum assisted keratoplasty Anterior and posterior lamellar techniques
